Disease-modifying osteoarthritis (OA) drugs (DMOADs) are needed as current OA therapies only relieve pain and do not alter the course of disease. In this article, Toll-like receptor 4 (TLR4) signalling, which is involved at various stages of pathogenesis, is reviewed, as is the potential for candidate TLR4-specific DMOADs.
- Rodolfo Gómez
- Amanda Villalvilla
- Gabriel Herrero-Beaumont
